Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Introduction of KRAS

Page View:

RAS is a family of GTPase proto-oncogenes, comprising three closely related RAS isoforms: HRAS, KRAS and NRAS.

From all of the RAS isoforms, KRAS is most frequently mutated.

KRAS mutations are particularly frequent in the pancreatic, lung and colorectal cancers.

KRAS gene is a proto-oncogene that encodes a GTP/GDP-binding protein that belongs to the GTPase RAS family.

The KRAS protein acts as molecular switchs that cycle between a GDP-bound inactive state and a GTP-bound active state.

KRAS protein switches between an inactive to an active form via binding to GTP and GDP(闪), respectively.

  • KRAS-targeted Drugs R&D Service.webp
    KRAS-targeted Drugs R&D Service

    In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides KRAS-targeted drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.

Relevant newsRelevant news